CN108969545A - Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease - Google Patents
Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease Download PDFInfo
- Publication number
- CN108969545A CN108969545A CN201811130862.0A CN201811130862A CN108969545A CN 108969545 A CN108969545 A CN 108969545A CN 201811130862 A CN201811130862 A CN 201811130862A CN 108969545 A CN108969545 A CN 108969545A
- Authority
- CN
- China
- Prior art keywords
- herb
- loosestrife root
- starflowerlike loosestrife
- starflowerlike
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The present invention relates to application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease.Inventor has found under study for action, and starflowerlike loosestrife root or herb can be by reducing the expression of uric acid in hematological system to the adjusting of correlative metabolites.This can further expand the operation strategies of starflowerlike loosestrife root or herb, can be used for the prevention and treatment (such as: kidney stone, obesity, dyslipidemia, coronary artery disease etc.) of a variety of uric acid induction diseases.
Description
Technical field
The invention belongs to biomedicine technical fields more particularly to starflowerlike loosestrife root or herb to prevent and treat the drug that uric acid induces disease in preparation
In application.
Background technique
Starflowerlike loosestrife root or herb is the herb of the narrow leaf Lysimachia sikokiana of Ofthe Primulaceae.Also known as it is " mappia foetida " that " starflowerlike loosestrife root or herb ", which is called,.Horse ratio
Wood is a kind of Chinese herbal medicine, has dispelling wind and eliminating dampness, the function of qi-regulating cold dispelling.
" the civil recipe collection in Guizhou ", " the civil medicinal herbs in Kweiyang " and " Guizhou herbal medicine " is on the books, also different name be infantile convulsion umbrella,
Yunna spiraea or public lindenleaf torricellia bark or leaf.Narrow leaf Lysimachia sikokiana perennial herb is about 30 centimetres high.Phytomorph fibrous root is faint yellow.Stem is grown thickly, regardless of
Branch, nearly base portion is red, there is pubescence.Upper green, section slightly expand, and have pubescence.The lower portion of the stem leaf is degenerated, and very little, such as flakey are right
It is raw；Stem top is verticillate, mostly 4-7 piece, differs in size, circle to obovate, 4-14 centimetres long, 2-10 centimetres wide, the anxious point of apex,
Full edge, slightly at ripple shape, base portion wealthy wedge shape to narrow wedge shape, above light it is green, below pale green；Petiole without or extremely short, purplish red.It is raw
In the dark and damp hayashishita in low-relief terrain and limes marginis.It is distributed the ground such as Sichuan, Guizhou.
It is recorded according to " Guizhou herbal medicine ", starflowerlike loosestrife root or herb is warm-natured, bitterly.With wind-dispelling, effect of invigorating blood circulation, for treating rheumatism numbness
Bitterly, hemiplegia, traumatic injury, the symptoms such as child convulsion.
Currently, being mostly to be used to treat above-mentioned illness for infantile convulsion umbrella and other components compatible use in prescription, for chasing after wind
Umbrella extracts product separation identification and carries out that mechanism etc. research is less, and not yet discovery starflowerlike loosestrife root or herb others are used from molecular level
The report on way has seriously affected starflowerlike loosestrife root or herb further genralrlization application.
Summary of the invention
In view of the problems of prior art, the present invention provides starflowerlike loosestrife root or herb and its new purposes of extract.
The technical scheme to solve the above technical problems is that
Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease.Specifically, starflowerlike loosestrife root or herb can be used alone
Or the drug for being used to prepare prevention and treatment uric acid induction disease is used in combination with other components.
Application of the starflowerlike loosestrife root or herb extract in the drug of preparation prevention and treatment uric acid induction disease.Specifically, starflowerlike loosestrife root or herb extract
It can be used alone or be used in combination with other components the drug for being used to prepare prevention and treatment uric acid induction disease.Such as: for making
The drug of the diseases such as standby prevention and treatment kidney stone, obesity, dyslipidemia or coronary artery disease.
The application of starflowerlike loosestrife root or herb or starflowerlike loosestrife root or herb extract in preparation reduction hematological system in the drug of the expression of uric acid.
It is urinated in hematological system specifically, starflowerlike loosestrife root or herb extract can be used alone or be used in combination to be used to prepare to reduce with other components
The drug of the expression of acid.
Starflowerlike loosestrife root or herb or starflowerlike loosestrife root or herb extract are lowering the application in xanthosine expression.Specifically, starflowerlike loosestrife root or herb or
Starflowerlike loosestrife root or herb extract can be used for preparing the drug for lowering xanthosine expression.
In the present invention, starflowerlike loosestrife root or herb is the narrow leaf Herba lysimachiae Paridiformis Lysimachia paridiformis of Ofthe Primulaceae
The drying herb of Franch.var.stenophylla Franch..
Above-mentioned, starflowerlike loosestrife root or herb extract is extracted by raw material of starflowerlike loosestrife root or herb, and starflowerlike loosestrife root or herb is the narrow leaf Herba lysimachiae Paridiformis of Ofthe Primulaceae
The drying herb of Lysimachia paridiformis Franch.var.stenophylla Franch..
Further, starflowerlike loosestrife root or herb extract extracts by the following method: by starflowerlike loosestrife root or herb pulverizing medicinal materials, with reflux extraction
Refluxing extraction is carried out to medicinal material using distilled water, collects extracting solution, concentration, freeze-drying obtain starflowerlike loosestrife root or herb extract.
Specifically, starflowerlike loosestrife root or herb extract can extract by the following method: starflowerlike loosestrife root or herb crushes, and uses 3-20 times of quality every time
Distilled water (quality of the distilled water used every time be starflowerlike loosestrife root or herb quality 3-20 times), with reflux extraction to starflowerlike loosestrife root or herb
It carries out refluxing extraction 0.5-4 hours, extracts 1-5 times in total, extracting solution is condensed into concentrate by combined extract, concentrate
Volume is the 1%-10% of the volume of the extracting solution after merging, and concentrate is freeze-dried, starflowerlike loosestrife root or herb extract is obtained.
Detailed description of the invention
Fig. 1 is the chromatogram that starflowerlike loosestrife root or herb extract is scanned using cation scan pattern；
Fig. 2 is the chromatogram that starflowerlike loosestrife root or herb extract is scanned using negative ion mode.
Specific embodiment
The principle and features of the present invention will be described below with reference to the accompanying drawings, and the given examples are served only to explain the present invention, and
It is non-to be used to limit the scope of the invention.
Starflowerlike loosestrife root or herb is the narrow leaf Herba lysimachiae Paridiformis Lysimachia paridiformis of Ofthe Primulaceae
The drying herb of Franch.var.stenophylla Franch..
1, the preparation of starflowerlike loosestrife root or herb extract
It 2000 grams of starflowerlike loosestrife root or herb medicinal material, is crushed, uses the distilled water (distilled water used every time of 10 times of quality every time
Quality be 20 kilograms), with reflux extraction to medicinal material carry out 2 hours of refluxing extraction, in total extract 3 times, merge extract
Extracting solution is concentrated into 2 liters by liquid, and concentrate is freeze-dried, and obtains 253 grams of starflowerlike loosestrife root or herb extract.
2, the measurement of starflowerlike loosestrife root or herb extract chromatography profile
(1) liquid-phase condition: Shimadzu Ultra Performance Liquid Chromatography instrument 30A (Japanese Shimadzu Corporation) is equipped with ACQUITY UPLCTM
HSS T3 chromatographic column (100mm × 2.1mm i.d., 1.8 μm) (Waters group company of the U.S.).Mobile phase A is that distilled water (contains
0.1% formic acid, w/w), Mobile phase B is acetonitrile (containing 0.1% formic acid, w/w).Column temperature is 40 DEG C, flow velocity 0.4ml/min, sample introduction
Amount is 5 μ l.Gradient elution method is shown in Table 1.Chromatograph efflux is directly injected into mass spectrograph without shunting and carries out negative ions scanning
Analysis.
1 UPLC eluent gradient elution process of table
A is 0.1% formic acid-water；B is 0.1% formic acid-acetonitrile
(2) it Mass Spectrometry Conditions: uses 4600 mass spectrograph of AB Sciex Triple TOF (American AB Sciex group company).
Cation scan pattern:
Ion spray voltage: ion source temperature: 5.5KV 600 DEG C, solves cluster voltage (DP): 100V, collision energy (CE):
35eV.Nitrogen is atomization gas and auxiliary gas: atomization gas 55psi, and auxiliary gas is 55psi, and gas curtain gas is 35psi.In m/z:
Full scan, integration time 160ms are carried out under 100-1000amu mass range ESI positive ion mode.IDA uses standard: each
Analyte, eight strongest fragment ions more than 100cps carry out daughter ion scanning in 100~1000amu mass range,
Accumulated time is 100ms.Collision voltage difference is 15eV, and dynamic background deducts DBS and opens.Automated calibration system (CDS) to MS and
MS/MS is tuned and corrects automatically.Data acquisition and processing analysis use2.1 softwares, MasterView are soft
Part.Work station:TF 1.7.1 software.
Anion scan pattern:
Ion spray voltage: ion source temperature: 4.0KV 600 DEG C, solves cluster voltage (DP): 100V, collision energy (CE):
35eV.Nitrogen is atomization gas and auxiliary gas, and atomization gas 65psi, auxiliary gas is 65psi, and gas curtain gas is 35psi.In m/z:
Full scan, integration time 160ms are carried out under 100-1000amu mass range ESI positive ion mode.IDA uses standard: Mei Gefen
Object is analysed, eight strongest fragment ions more than 100cps carry out daughter ion scanning in 100~1000amu mass range, tire out
The product time is 100ms.Collision voltage difference is 15eV, and dynamic background deducts DBS and opens.Automated calibration system (CDS) is to MS and MS/
MS is tuned and corrects automatically.Data acquisition and processing analysis are using use2.1 softwares, MasterView
Software.Work station:TF 1.7.1 software.
(3) chemical component is identified
Ingredient lists are imported into MasterView software, give its corresponding addition forms (POS:+H ,+NH4 ,+Na ,+K, 2M
+ H etc.；NEG:-H ,+Cl ,+FA-H etc.), establish Objective composition selection list.In conjunction with IDA type collection secondary data into
Row structure matching is scored at standard with document report, the information of network mass spectrometry database and comparative analysis.
Experimental result:
The chromatography map contour of starflowerlike loosestrife root or herb extract is as depicted in figs. 1 and 2.
Fig. 1 is the chromatography map contour of the positive ion mode of starflowerlike loosestrife root or herb extract,
Fig. 2 is the chromatography map contour of the negative ion mode of starflowerlike loosestrife root or herb extract；
Ingredient 1: alternariol, ion peak intensity are 1500-3000,
Ingredient 2: apiolin, ion peak intensity are 9000-13000,
Ingredient 3:7- hydroxycoumarin, ion peak intensity are 9000-13000,
Ingredient 4: camphanone, ion peak intensity are 500-2000,
Ingredient 5: luteolin, ion peak intensity are 20000-35000,
Ingredient 6: isorhamnetin-3-O-β-D-glycopranoside, ion peak intensity are 40000-60000,
Ingredient 7:5- methyl Kaempferol, ion peak intensity are 4000-8000,
Ingredient 8: robinin, ion peak intensity are 500-2000,
Ingredient 9:2,5- methyl dihydroxy benzoate, ion peak intensity are 1500-3000,
Ingredient 10: protocatechuic acid, ion peak intensity are 30000-60000,
Ingredient 11: Central China ilicin, ion peak intensity are 3000-6000.
3, animal packet and medication
Male SD rat (200g) is randomly divided into blank control group, starflowerlike loosestrife root or herb low dose group, starflowerlike loosestrife root or herb middle dose group, chases after
Wind umbrella high dose group.The dosage of starflowerlike loosestrife root or herb extract is 0.01g/kg-0.60g/kg, once a day oral administration, continuously
3-90 days.Blank control group gives same amount of normal saline 3-90 days, once a day.
Embodiment 1
Male SD rat is purchased from Si Beifu (Beijing) Bioisystech Co., Ltd, the number of the male SD rat of blank control group
Amount is 10, and the quantity of the male SD rat of starflowerlike loosestrife root or herb low dose group is 10, the male SD rat of starflowerlike loosestrife root or herb middle dose group
Quantity is 10, the quantity of the male SD rat of starflowerlike loosestrife root or herb high dose group is 10.The starflowerlike loosestrife root or herb of starflowerlike loosestrife root or herb low dose group extracts
The dosage of object is each 0.01-0.02g/kg, the dosage of the starflowerlike loosestrife root or herb extract of starflowerlike loosestrife root or herb middle dose group is each
0.03-0.04g/kg, starflowerlike loosestrife root or herb high dose group starflowerlike loosestrife root or herb extract dosage be each 0.05-0.06g/kg, daily
Oral administration is primary, for three days on end.Blank control group gives same amount of normal saline 3 days, oral daily primary.
Embodiment 2
Male SD rat is purchased from Si Beifu (Beijing) Bioisystech Co., Ltd, the number of the male SD rat of blank control group
Amount is 10, and the quantity of the male SD rat of starflowerlike loosestrife root or herb low dose group is 10, the male SD rat of starflowerlike loosestrife root or herb middle dose group
Quantity is 10, the quantity of the male SD rat of starflowerlike loosestrife root or herb high dose group is 10.The starflowerlike loosestrife root or herb of starflowerlike loosestrife root or herb low dose group extracts
The dosage of object is each 0.01-0.02g/kg, the dosage of the starflowerlike loosestrife root or herb extract of starflowerlike loosestrife root or herb middle dose group is each
0.03-0.04g/kg, starflowerlike loosestrife root or herb high dose group starflowerlike loosestrife root or herb extract dosage be each 0.05-0.06g/kg, daily
Oral administration is primary, and continuous 30 days.Blank control group gives same amount of normal saline 30 days, oral daily primary.
Embodiment 3
Male SD rat is purchased from Si Beifu (Beijing) Bioisystech Co., Ltd, the number of the male SD rat of blank control group
Amount is 10, and the quantity of the male SD rat of starflowerlike loosestrife root or herb low dose group is 10, the male SD rat of starflowerlike loosestrife root or herb middle dose group
Quantity is 10, the quantity of the male SD rat of starflowerlike loosestrife root or herb high dose group is 10.The starflowerlike loosestrife root or herb of starflowerlike loosestrife root or herb low dose group extracts
The dosage of object is each 0.01-0.02g/kg, the dosage of the starflowerlike loosestrife root or herb extract of starflowerlike loosestrife root or herb middle dose group is each
0.03-0.04g/kg, starflowerlike loosestrife root or herb high dose group starflowerlike loosestrife root or herb extract dosage be each 0.05-0.06g/kg, daily
Oral administration is primary, and continuous 90 days.Blank control group gives same amount of normal saline 90 days, oral daily primary.
4, sample collection and processing
Last dose for 24 hours after, from the abdominal aorta of each group rat collect blood sample, after waiting for blood to solidify,
2000rpm, 4 DEG C are centrifuged 10 minutes, carefully take out supernatant.Supernatant is collected, is frozen in -80 DEG C after packing.
5, metabonomic analysis
(1) liquid-phase condition: Shimadzu Ultra Performance Liquid Chromatography instrument 30A (Japanese Shimadzu Corporation) is equipped with ACQUI TY UPLCTM
HSS T3 chromatographic column (100mm × 2.1mm i.d., 1.8 μm) (Waters group company of the U.S.).Mobile phase A is that distilled water (contains
0.1% formic acid, w/w), Mobile phase B is acetonitrile (containing 0.1% formic acid, w/w).Column temperature is 40 DEG C, flow velocity 0.4ml/min, sample introduction
Amount is 5 μ l.It is as shown in table 2 to separate gradient.
2 efficient liquid phase eluent gradient elution process of table
(2) it Mass Spectrometry Conditions: uses 4600 mass spectrograph of AB Sciex Triple TOF (American AB Sciex group company).
Cation scan pattern:
Ion spray voltage: ion source temperature: 5.5KV 600 DEG C, solves cluster voltage (DP): 100V, collision energy (CE):
35eV.Nitrogen is atomization gas and auxiliary gas: atomization gas 55psi, and auxiliary gas is 55psi, and gas curtain gas is 35psi.In m/z:
Full scan, integration time 160ms are carried out under 100-1000amu mass range ESI positive ion mode.IDA uses standard: each
Analyte, eight strongest fragment ions more than 100cps carry out daughter ion scanning in 100~1000amu mass range,
Accumulated time is 100ms.Collision voltage difference is 15eV, and dynamic background deducts DBS and opens.Automated calibration system (CDS) to MS and
MS/MS is tuned and corrects automatically.Data acquisition and processing analysis use2.1 softwares, MasterView are soft
Part.Work station:TF 1.7.1 software.
Anion scan pattern:
Ion spray voltage: ion source temperature: 4.0KV 600 DEG C, solves cluster voltage (DP): 100V, collision energy (CE):
35eV.Nitrogen is atomization gas and auxiliary gas, and atomization gas 65psi, auxiliary gas is 65psi, and gas curtain gas is 35psi.In m/z:
Full scan, integration time 160ms are carried out under 100-1000amu mass range ESI positive ion mode.IDA uses standard: Mei Gefen
Object is analysed, eight strongest fragment ions more than 100cps carry out daughter ion scanning in 100~1000amu mass range, tire out
The product time is 100ms.Collision voltage difference is 15eV, and dynamic background deducts DBS and opens.Automated calibration system (CDS) is to MS and MS/
MS is tuned and corrects automatically.Data acquisition and processing analysis are using use2.1 softwares, MasterView
Software.Work station:TF 1.7.1 software.
6, statistical analysis: the screening criteria of difference metabolin: p-value < 0.05, VIP > 1.0 obtains difference metabolism
The analysis result of object.
Experimental result:
It is studied by metabolism group, it was found that the expression of 1726 metabolin ions in blood, with statistics side
Method carries out Analysis and Screening in these mass data, wherein the results are shown in Table 3 for the metabolism group of xanthosine.Inventor
It is found surprisingly that under study for action, after starflowerlike loosestrife root or herb is intervened, the expression of xanthosine is significantly lowered.Xanthosine can be with
It is changed into xanthine, is then changed into uric acid through xanthine oxidase again.
The difference metabolin of 3 starflowerlike loosestrife root or herb of table intervention rat blood serum
Currently, starflowerlike loosestrife root or herb is mainly used for the treatment of joint disease.But this research is found surprisingly that, starflowerlike loosestrife root or herb can lead to
The adjusting to correlative metabolites is crossed to reduce the expression of uric acid in hematological system.This can further expand the fortune of starflowerlike loosestrife root or herb
With range, can be used for a variety of uric acid induction diseases prevention and treatment (such as: kidney stone, obesity, dyslipidemia, coronary artery disease
Disease etc.).
Inventor has carried out multiple experiment again, for example, following manner, which is respectively adopted, extracts starflowerlike loosestrife root or herb extract:
Mode one, starflowerlike loosestrife root or herb is crushed, every time use 3 times of quality distilled water, with reflux extraction to starflowerlike loosestrife root or herb into
It row refluxing extraction 0.5 hour, extracts 1 time in total, extracting solution is condensed into concentrate by combined extract, and the volume of concentrate is
The 1% of the volume of extracting solution after merging, concentrate is freeze-dried, and obtains starflowerlike loosestrife root or herb extract.
Mode two, starflowerlike loosestrife root or herb is crushed, every time use 20 times of quality distilled water, with reflux extraction to starflowerlike loosestrife root or herb into
It row refluxing extraction 4 hours, extracts 5 times in total, combined extract, extracting solution is condensed into concentrate, the volume of concentrate is to close
The 10% of the volume of extracting solution after and, concentrate is freeze-dried, and obtains starflowerlike loosestrife root or herb extract.
The starflowerlike loosestrife root or herb extract that aforesaid way extracts is used for the experimental verification of the various embodiments described above respectively, the results showed that,
It can be urinated using the starflowerlike loosestrife root or herb extract that aforesaid way obtains by the adjusting to correlative metabolites to reduce in hematological system
The expression of acid.This can further expand the operation strategies of starflowerlike loosestrife root or herb, can be used for the prevention and treatment of a variety of uric acid induction diseases.
The foregoing is merely presently preferred embodiments of the present invention, is not intended to limit the invention, it is all in spirit of the invention and
Within principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.
Claims (9)
1. application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease.
2. application of the starflowerlike loosestrife root or herb extract in the drug of preparation prevention and treatment uric acid induction disease.
3. the medicine that starflowerlike loosestrife root or herb or starflowerlike loosestrife root or herb extract prevent and treat kidney stone, obesity, dyslipidemia or coronary artery disease in preparation
Application in object.
4. starflowerlike loosestrife root or herb or starflowerlike loosestrife root or herb extract reduce the application in hematological system in the drug of the expression of uric acid in preparation.
5. starflowerlike loosestrife root or herb or starflowerlike loosestrife root or herb extract are lowering the application in xanthosine expression.
6. application according to claim 1-5, which is characterized in that starflowerlike loosestrife root or herb is the narrow leaf landing of Ofthe Primulaceae
The drying herb of plum Lysimachia paridiformis Franch.var.stenophylla Franch..
7. according to the described in any item applications of claim 2-5, which is characterized in that starflowerlike loosestrife root or herb extract is mentioned by raw material of starflowerlike loosestrife root or herb
It takes, starflowerlike loosestrife root or herb is the narrow leaf Herba lysimachiae Paridiformis Lysimachia paridiformis of Ofthe Primulaceae
The drying herb of Franch.var.stenophylla Franch..
8. application according to claim 7, which is characterized in that starflowerlike loosestrife root or herb extract extracts by the following method: wind will be chased after
Umbrella pulverizing medicinal materials, refluxing extraction is carried out to medicinal material using distilled water with reflux extraction, collects extracting solution, concentration, freezing are dry
It is dry, obtain starflowerlike loosestrife root or herb extract.
9. application according to claim 8, which is characterized in that starflowerlike loosestrife root or herb extract extracts by the following method: starflowerlike loosestrife root or herb
It crushes, uses the distilled water of 3-20 times of quality every time, starflowerlike loosestrife root or herb is carried out refluxing extraction 0.5-4 hours with reflux extraction,
It extracts 1-5 times in total, combined extract, extracting solution is condensed into concentrate, the volume of concentrate is the extracting solution after merging
The 1%-10% of volume, concentrate is freeze-dried, and obtains starflowerlike loosestrife root or herb extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811130862.0A CN108969545A (en) | 2018-09-27 | 2018-09-27 | Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811130862.0A CN108969545A (en) | 2018-09-27 | 2018-09-27 | Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108969545A true CN108969545A (en) | 2018-12-11 |
Family
ID=64542976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811130862.0A Pending CN108969545A (en) | 2018-09-27 | 2018-09-27 | Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108969545A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040176306A1 (en) * | 1998-07-31 | 2004-09-09 | Sacks Meir S. | Compositions for raising uric acid levels and methods of using the same |
| CN101926896A (en) * | 2010-06-22 | 2010-12-29 | 贵州百灵企业集团制药股份有限公司 | Traditional Chinese medicinal preparation for treating gout and preparation method thereof |
| CN105004833A (en) * | 2015-05-25 | 2015-10-28 | 贵州百灵企业集团制药股份有限公司 | Detection method for traditional Chinese medicine preparation for treating acute gouty arthritis and gout |
-
2018
- 2018-09-27 CN CN201811130862.0A patent/CN108969545A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040176306A1 (en) * | 1998-07-31 | 2004-09-09 | Sacks Meir S. | Compositions for raising uric acid levels and methods of using the same |
| CN101926896A (en) * | 2010-06-22 | 2010-12-29 | 贵州百灵企业集团制药股份有限公司 | Traditional Chinese medicinal preparation for treating gout and preparation method thereof |
| CN105004833A (en) * | 2015-05-25 | 2015-10-28 | 贵州百灵企业集团制药股份有限公司 | Detection method for traditional Chinese medicine preparation for treating acute gouty arthritis and gout |
Non-Patent Citations (4)
| Title |
|---|
| EWA KULIKOWSKA,等: "Xanthine, xanthosine and its nucleotides: solution structures of neutral and ionic forms, and relevance to substrate properties in various enzyme systems and metabolic pathways", 《ACTA BIOCHIMICA POLONICA》 * |
| 南京中医药大学: "《中药大辞典》", 30 June 2014, 上海科学技术出版社 * |
| 荆云,等: "中成药治疗痹证的研究近况", 《云南中医学院学报》 * |
| 黄旭龙,等: "苗药追风伞的研究进展", 《黑龙江农业科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1463412B1 (en) | Composition comprising wenguanguo extracts, methods for preparing same and uses therof | |
| AU2002348988A1 (en) | Composition comprising Wenguanguo extracts, methods for preparing same and uses thereof | |
| Li et al. | Spectrum-effect relationship of antioxidant and tyrosinase activity with Malus pumila flowers by UPLC-MS/MS and component knock-out method | |
| US7491414B2 (en) | Anti-inflammatory substances extracted from Echinacea | |
| Peng-Peng et al. | Metabolomics analysis and rapid identification of changes in chemical ingredients in crude and processed Astragali Radix by UPLC-QTOF-MS combined with novel informatics UNIFI platform | |
| Ye et al. | Identification and characterization of key chemical constituents in processed Gastrodia elata using UHPLC-MS/MS and chemometric methods | |
| EP2432891B1 (en) | Methods for preparing a fermented ginseng concentrate or powder | |
| Quyen et al. | Evaluation of total polyphenol content, total flavonoid content, and antioxidant activity of Centella asiatica | |
| Gattuso et al. | Morphoanatomical studies of Uncaria tomentosa and Uncaria guianensis bark and leaves | |
| Wang et al. | A review of the botany, traditional uses, phytochemistry and pharmacology of Stemonae Radix | |
| CN108969545A (en) | Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment uric acid induction disease | |
| CN101254217B (en) | Preparation of extract of regeneratabl portion of yew and applications of same for preparing oral anti-cancer medicine | |
| CN108478609A (en) | Application of the starflowerlike loosestrife root or herb in induced platelet aggregation | |
| CN108938688A (en) | Application of the starflowerlike loosestrife root or herb in the drug for preparing anti-norepinephrine induction disease | |
| CN109106734A (en) | Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment er stress induction disease | |
| CN108403735A (en) | Application of the starflowerlike loosestrife root or herb in the expression for lowering maltose-glucoamylase | |
| CN108938689A (en) | Application of the starflowerlike loosestrife root or herb in preparation enhancing hematological system immunity drug | |
| KR100570803B1 (en) | A process of extracting glabridine from licorice root | |
| Rai et al. | In vitro immuno-stimulatory and anticancer activities of Oroxylum indicum (L.) Kurz.: An evidence for substitution of aerial parts for conservation | |
| CN114588184B (en) | Herba Saururi extract, and preparation method and application thereof | |
| CN108354954A (en) | Starflowerlike loosestrife root or herb is preparing the application for promoting blood platelet in the drug that synovium of joint is assembled | |
| CN114106008A (en) | Diterpene quinone compound extracted and separated from salvia miltiorrhiza bunge and method and application thereof | |
| CN108354955A (en) | Application of the starflowerlike loosestrife root or herb in preparing the drug for repairing joint injury | |
| Kondamudi et al. | Harpagoside Content in Devil's Claw Extracts | |
| Liu | Standardization and identification of minor components of silymarin (MK-001) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181211 |